Search our Database of Scientific Publications and Authors

I’m looking for a
    [Analysis of the Cochrane Review: Pharmacotherapy for Hyperuricemia in Hypertensive Patients. Cochrane Database Syst Rev. 2017;4:CD008652.]
    Acta Med Port 2017 May 31;30(5):356-360. Epub 2017 May 31.
    Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Centro Colaborador Português da Rede Cochrane Iberoamericana. Lisboa. Portugal.
    Arterial hypertension is a public health problem that affects approximately 25% of the world's adult population. The association between hypertension and hyperuricemia has been shown on epidemiological and experimental studies. However, it is unclear whether lowering serum uric acid might lower blood pressure. This Cochrane systematic review - a revised edition of a previously published one - intended as primary objective to evaluate the effect of hypouricemic drugs in patients with primary hypertension or prehypertension. The secondary objectives were to evaluate the efficacy and safety of hypouricemic drugs. A systematic search until February 2016 on controlled, randomized or quasi-randomized trials comparing the effect of hypouricemic drug versus placebo in hypertensive or prehypertensive patients was performed on the following databases: The Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, The World Health Organization International Clinical Trials Registry Platform, e ClinicalTrials.gov. LILACS database up to March 2016 was also searched and the authors of relevant studies were contacted. There were 349 identified papers, 21 were preselected and three randomized clinical trials (211 patients) were included in the qualitative analysis and in the meta-analysis. Two of the trials were conducted exclusively on adolescents. The authors conclude that hypouricemic drugs are not effective in lowering blood pressure in patients with hyperuricemia and primary prehypertension or hypertension. However, this strategy might be more effective in the specific population of adolescents with prehypertension or mild primary hypertension recently diagnosed. Hypouricemic drugs effectively reduce serum uric acid level and withdrawals of therapy due to adverse effects were not superior in the treated group, comparing to placebo; however, one patient withdrew due to a severe cutaneous reaction.

    Similar Publications

    Pharmacotherapy for hyperuricemia in hypertensive patients.
    Cochrane Database Syst Rev 2017 04 13;4:CD008652. Epub 2017 Apr 13.
    Nephrology, Rio de Janeiro State University, Av. 28 de setembro, 87, Vila Isabel, Rio de Janeiro, Rio de Janeiro, Brazil, 20551030.
    Background: High blood pressure represents a major public health problem. Worldwide, approximately one-fourth of the adult population has hypertension. Epidemiological and experimental studies suggest a link between hyperuricemia and hypertension. Read More
    Pharmacotherapy for hyperuricemia in hypertensive patients.
    Cochrane Database Syst Rev 2013 Jan 31(1):CD008652. Epub 2013 Jan 31.
    Nephrology Department and Intensive Care Unit, Centro Médico de Campinas - Campinas - SP, Campinas, Brazil.
    Background: High blood pressure represents a major public health problem. Worldwide, approximately one fourth of the adult population has hypertension. Epidemiological and experimental studies suggest a linkage between hyperuricemia and hypertension. Read More
    Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.
    Cochrane Database Syst Rev 2016 Mar 10;3:CD007451. Epub 2016 Mar 10.
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, Canada, V6T 1Z3.
    Background: Beta blockers are commonly used to treat hypertension. The blood pressure reading is the primary tool for physicians and patients to assess the efficacy of the treatment. The blood pressure lowering effect of beta-1 selective blockers is not known. Read More
    Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Cochrane Database Syst Rev 2017 04 5;4:CD007066. Epub 2017 Apr 5.
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada, V6T 1Z3.
    Background: Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors are a new class of drugs that decrease blood pressure (BP) by preventing the formation of both angiotensin I and angiotensin II. Read More